# Virginia governor announces cannabis plan to pass this month (Newsletter: June 17, 2026) > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/virginia-governor-announces-cannabis-plan-to-pass-this-month-newsletter-june-17-2026/ > **Published:** 2026-06-17T12:20:33-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:52:07-04:00 > **Clinical Summary:** Cannabinoids show promise for Alzheimer's agitation in trials. What clinicians need to know about efficacy, dosing, and safety in dementia care. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyNeurologyResearchCBDAging[Mental Health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/)Safety Why This Matters Clinicians treating Alzheimer’s disease patients with agitation and neuropsychiatric symptoms now have emerging evidence supporting cannabinoid-based therapies as a potential treatment option, pending Virginia’s regulatory framework which could affect medication access and clinical implementation. As state-level legalization progresses, clinicians need clear guidance on dosing, drug interactions, and patient selection criteria for cannabinoid therapies to safely integrate them into standard dementia care protocols. Regulatory clarity from Virginia and other states will determine whether clinicians can routinely prescribe these therapies and whether insurance coverage becomes available for patients who might benefit. Clinical Summary Virginia’s announced [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) plan, expected to pass in June 2026, will likely expand [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) to cannabinoid-based therapies at a time when clinical evidence increasingly supports their use in neuropsychiatric conditions. Recent evidence demonstrates that cannabinoid therapies produce measurable improvements in agitation and neuropsychiatric symptoms in Alzheimer’s disease patients compared to placebo, suggesting a legitimate clinical role for these agents in managing behavioral symptoms that often complicate dementia care. As Virginia moves toward legalization, clinicians in the state will need to develop protocols for patient evaluation, product selection, and monitoring, particularly given the potential benefits in elderly populations suffering from dementia-related behavioral disturbances. The regulatory framework that accompanies legalization will be critical in ensuring product standardization and quality, which are essential for achieving the clinical outcomes demonstrated in research. This convergence of policy change and emerging clinical evidence creates both an opportunity and a responsibility for Virginia clinicians to thoughtfully integrate cannabinoid therapies into their practice for appropriate patient populations. Clinicians should begin preparing now to discuss evidence-based cannabinoid options with patients experiencing agitation or neuropsychiatric symptoms related to Alzheimer’s disease, while awaiting final regulatory guidance on product standards and dosing. Dr. Caplan’s Take “The review showing cannabinoid-based therapies outperforming placebo on agitation and neuropsychiatric symptoms in Alzheimer’s disease is promising, but we need to understand the quality and size of those underlying trials before integrating this into standard practice, and we certainly need longer-term safety data before recommending cannabis products to our most vulnerable patients.” Clinical Perspective 💊 As Virginia moves toward [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/), emerging evidence suggests potential therapeutic applications in neurodegenerative disease, particularly for managing behavioral and neuropsychiatric symptoms in Alzheimer’s disease patients. However, clinicians should recognize substantial limitations in the current evidence base, including small sample sizes, heterogeneous [cannabinoid formulations](https://cedclinic.com/brazil-cannabis-regulatory-framework-new-medical-rules/), variable dosing regimens, and the challenge of disentangling placebo effects in symptomatic populations where expectancy effects are particularly pronounced. The regulatory landscape remains fragmented, with [FDA approval](https://cedclinic.com/medicare-cannabis-reimbursement-policy-fda-approval/) limited to specific cannabinoid products while most cannabis preparations available through state-legal channels lack rigorous pharmacokinetic characterization or long-term safety data in elderly populations. Clinicians encountering patients or families inquiring about cannabis for cognitive or behavioral symptoms in dementia should acknowledge the preliminary supportive data while emphasizing the need for carefully controlled trials, standardized dosing, and interaction studies with common medications in this pol 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Virginia%20governor%20announces%20cannabis%20plan%20to%20pass%20this%20month%20%28Newsletter%3A%20June%2017%2C%202026%29%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59435)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59435)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Virginia%20governor%20announces%20cannabis%20plan%20to%20pass%20this%20month%20%28Newsletter%3A%20June%2017%2C%202026%29%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59435)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 405 Items — March 12, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-2026-spring-launch/) - [CED Digest: 392 Items — March 11, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) 📰 Source: [https://www.marijuanamoment.net/virginia-governor-announces-cannabis-plan-to-pass-this-month-newsletter-june-17-2026/](https://www.marijuanamoment.net/virginia-governor-announces-cannabis-plan-to-pass-this-month-newsletter-june-17-2026/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).